A GHRH analog paired with a ghrelin mimetic. In a Phase 1 trial in healthy adults, a single dose of CJC-1295 raised mean IGF-1 levels 1.5–3x above baseline for 6+ days (Teichman et al., JCEM 2006).
$52.0 per daily dose
Start Free AssessmentGet started in 3 simple steps. No office visits required.
Answer a few health questions. Our board-certified physicians review your medical history and determine if CJC-1295 / Ipamorelin is right for you.
If approved, your prescription is sent to our partner pharmacy. Your medication is compounded fresh and shipped directly to your door.
Inject nightly at home. Track your progress with our app. Our care team is available 24/7 for support and dose adjustments.
Advanced peptide therapy for targeted healing and optimization.
2-10x increase in GH and IGF-1 levels
Stimulates gh secretion via ghrh-r and ghs-r1a
Inject nightly at home with guided support
Supports natural healing and recovery pathways
Phase 2 results demonstrating efficacy and safety.
Phase 2 data — Teichman et al., J Clin Endocrinol Metab 2006. CJC-1295 / Ipamorelin demonstrates significant clinical efficacy.
Mechanism of Action
Stimulates gh secretion via ghrh-r and ghs-r1a
Specifically designed to address tissue damage and recovery
Activates natural repair mechanisms at the cellular level
Important information about CJC-1295 / Ipamorelin safety and side effects.
Everything you need to know about CJC-1295 / Ipamorelin.
CJC-1295 / Ipamorelin is a ghrh analog + ghrelin mimetic — stimulates gh secretion via ghrh-r and ghs-r1a. Our physicians prescribe it based on your individual health profile to achieve optimal therapeutic outcomes.
Based on clinical evidence, 2-10x increase in GH and IGF-1 levels. Individual results vary based on adherence, health status, and other factors. Our care team monitors your progress throughout treatment.
CJC-1295 / Ipamorelin is administered via subcutaneous injection nightly. Your shipment includes pre-filled syringes, alcohol swabs, and a sharps container. Our care team provides injection training.
The most common side effects include Injection site reaction, Water retention, Increased appetite. These are typically mild and may improve over time. Our physicians monitor your response and can adjust dosing to minimize side effects. Contact our care team if you experience any concerning symptoms.
CJC-1295 / Ipamorelin is a research peptide used under physician supervision. While not FDA-approved for specific indications, it is legally prescribed by our board-certified physicians based on clinical evidence. All peptides are sourced from FDA-registered pharmacies with third-party purity testing.
Real reviews from verified ArgoMD patients.
Started CJC-1295 / Ipamorelin for recovery after a shoulder injury. Within weeks I noticed reduced pain and faster healing than my PT expected. Impressed.
As someone who trains hard, CJC-1295 / Ipamorelin has been a game changer for recovery. Less soreness, faster return to training, and my joints feel better overall.
My physician at ArgoMD recommended CJC-1295 / Ipamorelin as part of my optimization protocol. The quality is excellent and the results speak for themselves.
CJC-1295 / Ipamorelin is a prescription medication compounded by a U.S. 503A pharmacy pursuant to a valid prescription from a state-licensed physician for an identified patient. It is prescribed as a compounded preparation and is not FDA-approved for any indication. It is not a dietary supplement and is not governed by DSHEA. Regulatory disclosure: the FDA has placed CJC-1295 and Ipamorelin on the 503A Category 2 list of bulk drug substances, indicating the agency has identified significant safety concerns and that these substances are not currently included on the official 503A bulks list. The FDA's position is evolving and has not been finalized. ArgoMD's 503A pharmacy partner currently compounds these peptides under its own legal interpretation of the applicable rules; this interpretation is not an FDA endorsement. Patients should independently verify the current FDA status of CJC-1295 and Ipamorelin (search: "FDA 503A Category 2 bulk drug substances") before deciding to start, and should understand that future regulatory action could change or end access. Contraindicated in active or suspected malignancy. Use during pregnancy or breastfeeding is not established. May affect glucose metabolism; discuss with your physician if you have diabetes or pre-diabetes. Common side effects include injection site reaction, transient water retention, and increased appetite. This page describes a medication available only by prescription after physician review; eligibility is not guaranteed. © 2026 ArgoMD.
Join patients optimizing their recovery with ArgoMD peptide protocols.
Get Started — $312/month